Saltar al contenido principal
xMedica

NCT06956014ClinicalTrials.gov

Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy

Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of the Full-spectrum Cannabis Extract VER-01 in Participants With Chronic Painful Lumbosacral Radiculopathy

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

The aim of the trial is to prove the efficacy and safety of VER-01 compared to placebo in patients with chronic painful lumbosacral radiculopathy (PLSR) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not…

Fase 3810 participantes buscados43 centros1 país

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2025-05-02; recorded start 2026-09-22
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 2 other studies in this databaseCounted from the lead sponsor named in the record (Vertanical GmbH)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 810 participants (target), run at 43 sites.

How this score is built
  • Enrolment29/40

    810 participants (target)

  • Site count0/25

    Site count not stated in the record

  • Country count0/15

    Country count not stated in the record

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale1/10

    Vertanical GmbH has led 3 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

The aim of the trial is to prove the efficacy and safety of VER-01 compared to placebo in patients with chronic painful lumbosacral radiculopathy (PLSR) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

Afecciones

  • Lumbosacral Radiculopathy

Elegibilidad

Elegibilidad
SexoTodos
Edades18 Years – Sin máximo
Voluntarios sanosNo

Elegibilidad tal como figura en el registro

Inclusion Criteria: * Participants ≥ 18 years of age, all sexes * Participant voluntarily provided written informed consent * Participant is willing and able to comply with scheduled visits, treatment plan, eDiary, and other trial-related procedures throughout trial participation Exclusion Criteria: * Pregnant or breastfeeding female patients * Known history of previous or current severe psychiatric disorder as per DSM-5 (e.g., schizophrenia, bipolar disorder, severe anxiety disorder, psychotic disorder, post-traumatic stress disorder), or currently taking antipsychotic medication * Cardiovascular event or clinically significant cardiac dysfunction (e.g., congestive heart failure, myocardial ischemia, arrhythmias, poorly controlled high blood pressure, congenital long QT syndrome) within 12 months or a cardiac disorder that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioDe intervención
FaseFase 3
AsignaciónAleatorizado
Modelo de intervenciónPARALLEL
Propósito principalTREATMENT
EnmascaramientoQUADRUPLE (4)
Inscripción810 participantes buscados

Patrocinador y colaboradores

  • Vertanical GmbH Patrocinador

Grupos e intervenciones

  • VER-01 Dose 1EXPERIMENTAL
  • VER-01 Dose 2EXPERIMENTAL
  • PlaceboPLACEBO_COMPARATOR

Intervenciones

  • Otro Placebo

    Comparator without active ingredient

  • Fármaco VER-01

    Standardized soft extract from Cannabis sativa DKJ127 L., cannabis flos (Cannabis flower), corresponding to 19 mg Δ9-Tetrahydrocannabinol (THC) per ml drug product

Variables de resultado

  1. Variable de resultado principal

    Efficacy based on pain reduction

    The primary endpoint is the absolute change in mean leg pain intensity in the index leg measured on an 11-point numerical rating scale (NRS) at Treatment Week 12 compared to Baseline.

    Plazo From Baseline to Treatment Week 12

Fechas

Fechas
Fecha de inicio22 de septiembre de 2026 (real)
Finalización principal1 de septiembre de 2028 (estimada)
Finalización1 de septiembre de 2028 (estimada)
Primera publicación2 de mayo de 2025 (real)
Última actualización19 de noviembre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última veznoviembre de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

43 centros están en reclutamiento

United States

United States
CentroCiudadEstado o regiónEstado
Central Texas Clinical Research, LLCAustinTexasEn reclutamiento
Boston Clinical TrialsBostonMassachusettsEn reclutamiento
Bradenton Research CenterBradentonFloridaEn reclutamiento
DFW Clinical TrialsCarrolltonTexasEn reclutamiento
Epic Medical Research - CarroltonCarrolltonTexasEn reclutamiento
Clinitiative - Clinical Trials of South Carolina - CharlestonCharlestonSouth CarolinaEn reclutamiento
Epic Medical Research - ChickashaChickashaOklahomaEn reclutamiento
Velocity Clinical Research - ClevelandClevelandOhioEn reclutamiento
Epic Medical Research - DeSotoDeSotoTexasEn reclutamiento
Mountain View Clinical ResearchDenverColoradoEn reclutamiento
Innovare Research Group IFriendswoodTexasEn reclutamiento
AGA Clinical TrialsHialeahFloridaEn reclutamiento
HD Research - Memorial Hermann VillageHoustonTexasEn reclutamiento
Perfizien Clinical Research LLCHoustonTexasEn reclutamiento
Synergy Groups Medical - Southeast HoustonHoustonTexasEn reclutamiento
Green Leaf Clinical TrialsJacksonvilleFloridaEn reclutamiento
R & H Clinical ResearchKatyTexasEn reclutamiento
Alliance for Multispecialty Research - KnoxvilleKnoxvilleTennesseeEn reclutamiento
Epic Clinical Research - LewisvilleLewisvilleTexasEn reclutamiento
Central Medical Research InstituteLong BeachCaliforniaEn reclutamiento
Tekton Research - LongmontLongmontColoradoEn reclutamiento
K2 Medical Research - Maitland IIMaitlandFloridaEn reclutamiento
Velocity Clinical Research - MedfordMedfordOregonEn reclutamiento
Alma Clinical ResearchMiamiFloridaEn reclutamiento
Floridian Research Institute LLC IMiamiFloridaEn reclutamiento
AMR MobileMobileAlabamaEn reclutamiento
Monroe Biomedical Research - MonroeMonroeNorth CarolinaEn reclutamiento
Alliance for Multispecialty Research - NorfolkNorfolkVirginiaEn reclutamiento
Conquest Research - Lake NonaOrlandoFloridaEn reclutamiento
Alfa Medical Research - Pembroke PinesPembroke PinesFloridaEn reclutamiento
Flourish Research - PhiladelphiaPlymouth MeetingPennsylvaniaEn reclutamiento
United Medical ResearchPort OrangeFloridaEn reclutamiento
Boeson ResearchProvoUtahEn reclutamiento
CenExel JBR - Salt Lake CitySalt Lake CityUtahEn reclutamiento
Elixia Clinical Research CollaborativeSpringfieldMassachusettsEn reclutamiento
Professional Health Care of PinellasSt. PetersburgFloridaEn reclutamiento
Velocity Clinical Research - SuffolkSuffolkVirginiaEn reclutamiento
Alliance for Multispecialty Research - Tempe ITempeArizonaEn reclutamiento
Alliance for Multispecialty Research - Wichita EastWichitaKansasEn reclutamiento
Grayline Research CenterWichita FallsTexasEn reclutamiento
Progressive Medicine of the Triad, LLCWinston-SalemNorth CarolinaEn reclutamiento
Conquest Research - Winter ParkWinter ParkFloridaEn reclutamiento
Vitalix ClinicalWorcesterMassachusettsEn reclutamiento

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

  1. 19 de noviembre de 2026

    Centro añadido

    11 sites added (43 total)

    3243

  2. 2 de noviembre de 2026

    Centro añadido

    9 sites added (32 total)

    2332

  3. 21 de octubre de 2026

    Centro añadido

    1 site added (23 total)

    2223

  4. 19 de octubre de 2026

    Centro añadido

    21 sites added (22 total)

    122

  5. 28 de septiembre de 2026

    Estado modificado

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  6. 28 de septiembre de 2026

    Centro añadido

    1 site added (1 total)

    01

  7. 28 de septiembre de 2026

    Reclutamiento abierto

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING